Published in TB and Outbreaks Week, July 21st, 2009
"Survival throughout the study was 60% for the AFG5+VRC group, 50% for the VRC...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.